Panobinostat in combination with rituximab in heavily pretreated diffuse large B‐cell lymphoma: Results of a phase II study

This is a phase II study of panobinostat, an oral pan‐HDAC inhibitor, combined with rituximab in patients with relapsed diffuse large B cell lymphoma. Panobinostat was administered orally 3 times a week every other week on a 28‐day cycle. Rituximab was administered weekly during the first cycle, the...

Full description

Saved in:
Bibliographic Details
Published in:Hematological oncology 2018-10, Vol.36 (4), p.633-637
Main Authors: Barnes, Jeffrey A., Redd, Robert, Fisher, David C., Hochberg, Ephraim P., Takvorian, Tak, Neuberg, Donna, Jacobsen, Eric, Abramson, Jeremy S.
Format: Article
Language:English
Subjects:
Anemia
Anorexia
B-cell lymphoma
Diarrhea
diffuse large B cell lymphoma
Fatigue
Histone deacetylase
histone deacetylase inhibitor
Hypophosphatemia
Immunotherapy
Lymphocytes B
Lymphoma
Lymphopenia
Monoclonal antibodies
Nausea
non‐Hodgkin lymphoma
panobinostat
Patients
Rituximab
Targeted cancer therapy
Thrombocytopenia
Toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This is a phase II study of panobinostat, an oral pan‐HDAC inhibitor, combined with rituximab in patients with relapsed diffuse large B cell lymphoma. Panobinostat was administered orally 3 times a week every other week on a 28‐day cycle. Rituximab was administered weekly during the first cycle, then on Day 1 of cycles 2 to 6. Patients without disease progression after 6 cycles continued panobinostat monotherapy for up to 6 additional cycles in the absence of disease progression. Eighteen eligible subjects were enrolled, and 18 were evaluable for response. The overall response rate was 11% (90% CI [2%‐34%]) with 2 subjects having a partial response. The duration of response in these subjects was 51 and 60 days. Five additional subjects had stable disease with 3 subjects having tumor reduction between 27 and 44%, not meeting criteria for partial response. One subject with stable disease remained on therapy a total of 12 cycles. The most common toxicities while on study were thrombocytopenia (14 patients, 78%); fatigue (11, 61%); anemia (10, 56%); diarrhea (8, 44%); and nausea, lymphopenia, anorexia, and hypophosphatemia (5 each, 28% of patients), the majority of which was grade 2 or less. These data indicate that the combination of panobinostat with rituximab is able to induce responses in a limited number of subjects with relapsed diffuse large B cell lymphoma.
ISSN:0278-0232
1099-1069
DOI:10.1002/hon.2515